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Human mesenchymal stem cells (hMSCs) are one of the 
most widely researched stem cell types with broad appli-
cations from basic research to therapeutics, the majority 
of which require introduction of exogenous DNA. How-
ever, safety and scalability issues hinder viral delivery, 
while poor efficiency hinders nonviral gene delivery, par-
ticularly to hMSCs. Here, we present the use of a phar-
macologic agent (glucocorticoid) to overcome barriers 
to hMSC DNA transfer to enhance transfection using 
three common nonviral vectors. Glucocorticoid prim-
ing significantly enhances transfection in hMSCs, dem-
onstrated by a 3-fold increase in efficiency, 4–15-fold 
increase in transgene expression, and prolonged trans-
gene expression when compared to transfection without 
glucocorticoids. These effects are dependent on gluco-
corticoid receptor binding and caused in part by main-
tenance of normal metabolic function and increased 
cellular (5-fold) and nuclear (6–10-fold) DNA uptake 
over hMSCs transfected without glucocorticoids. Results 
were consistent across five human donors and in cells up 
to passage five. Glucocorticoid cell priming is a simple 
and effective technique to significantly enhance nonviral 
transfection of hMSCs that should enhance their clinical 
use, accelerate new research, and decrease reliance on 
early passage cells.
Received 20 August 2015; accepted 12 October 2015; advance online  
publication 17 November 2015. doi:10.1038/mt.2015.195
INTRODUCTION
Human mesenchymal stem cells (hMSCs) have become one of 
the most widely researched stem cell types in recent years due 
to multiple unique properties. hMSCs are capable of in vitro tri-
lineage differentiation (ectoderm, mesoderm, and endoderm)1,2 
and can be derived from multiple, abundant sources within the 
body including bone marrow,3 fat,4 skin,5 muscle,6 and peripheral 
blood.7 hMSCs also offer advantages over other stem cell types 
in that they can be ethically derived from adults, are nontumori-
genic, and are immunoprivileged.8,9 For these reasons, hMSCs 
are under much investigation for uses in tissue engineering and 
regenerative medicine,10 for the targeted delivery and secretion 
of therapeutic proteins,11,12 and for use in cancer therapy.2 All of 
these applications either require or would be greatly aided by the 
introduction of exogenous DNA to encode genes for tissue growth 
factors, to genetically guide differentiation, or induce production 
of therapeutic proteins.
Unfortunately, current gene delivery techniques to hMSCs 
through viral and nonviral methods have shortcomings. Viral gene 
delivery is highly efficient, yet costly and difficult to produce, with 
limited genetic cargo capacity, and is prone to safety concerns,13,14 
particularly in hMSCs. Furthermore, hMSCs are frequently used 
in ex vivo therapies, where viral vectors retained within the cells 
could be released upon implantation into surrounding tissues 
where those viral vectors may initiate a host immune response, 
become mutagenic, or even tumorigenic.15,16 Conversely, nonviral 
gene delivery is considerably safer by comparison to viral deliv-
ery, with the added advantages of being inexpensive, simple to 
produce, and not limited by genetic cargo size; however, nonvi-
ral delivery is comparably less efficient,17 particularly to hMSCs. 
Most nonviral gene delivery methods to hMSCs report transfec-
tion efficiencies between 1–10% of cells expressing transgene,18–21 
with transfection efficiencies reported as high as 20% only to cells 
at passages one or two.19–21 For hMSCs to be therapeutically via-
ble while maintaining patient safety, more efficient nonviral gene 
delivery strategies must be developed. The primary approach to 
improve nonviral gene delivery is chemical modification exist-
ing vectors or de novo synthesis, however this approach has not 
produced significant increases in the efficient transfection of 
hMSCs.18,20 An alternative approach to improving gene delivery is 
to prime cells with a pharmacologic agent to transiently overcome 
barriers of gene delivery for improved transfection.22–24
A potential family of priming agent is glucocorticoids (GC), 
which are steroid hormones that regulate metabolic activity by 
binding the GC receptor and translocating to the nucleus, where 
the receptor acts as a transcription factor to modulate gene expres-
sion.25,26 GCs are used widely in the clinic for their potent anti-
inflammatory properties. Additionally, dexamethasone (DEX), a 
synthetic GC, has been shown to dilate nuclear pores of Xenopus 
laevis oocytes up to 300 nm in diameter27,28 and increase micro-
somal membrane fluidity in fetal rat livers29; properties that could 
enhance cellular and nuclear entry of delivered exogenous DNA. 
GCs such as DEX and the natural GC, cortisol, have also been 
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used to modify polymer- and lipid-based gene delivery systems 
for nuclear targeting and decreased immune response,30,31 and 
to prime δ some human and murine immortalized cell lines for 
transfection.32,33 Additionally, DEX has been shown to have no 
negative effect on the multipotency of hMSCs, in fact enhancing 
their trilineage differentiation34 and immunomodulatory prop-
erties.35 Due to the promising properties of GCs to potentially 
overcome some of the barriers to efficient gene delivery, GCs were 
studied as potential cell priming adjuvants for enhanced transfec-
tion to hMSCs.
In this report, we present the effects of GC-priming on bone 
marrow-derived hMSC transfection outcomes across multiple cell 
donors, transgenes, and commercially available nonviral reagents. 
We also demonstrate maintenance of normal hMSC functions, 
preserving the inherent safety of nonviral gene delivery, and pro-
vide a partial mechanistic understanding behind the effects of 
GC-mediated cell-priming on nonviral gene delivery.
RESULTS
Cell priming enhances transfection outcomes
Two GCs were evaluated as cell priming adjuvants for enhanc-
ing nonviral transfection in passage four, bone marrow-derived 
hMSCs. Cells (Table 1) were pretreated with varying doses of 
DEX or cortisol, over a range of physiological concentrations, 30 
minutes prior to delivery of Lipofectamine-LTX (LF-LTX) lipo-
plexes containing the pEGFP-LUC plasmid. Thirty minutes were 
determined to be optimal GC pretreatment timing in a separate 
experiment (Supplementary Figure S1). For all experiments, 
GC-primed cells were compared to standard transfection in basal 
media (BM) and transfection in media with an equivalent volume 
of GC vehicle (EtOH). Transfection outcomes were measured as 
luciferase (LUC) expression levels, normalized to total protein 
levels. While transfection in BM and vehicle control (EtOH) were 
not statistically different from each other, GC-primed cells exhib-
ited statistically increased transfection with increasing GC dose, 
similar to a classic dose–response curve (Figure 1). Compared to 
controls, LUC expression in primed cells began to increase at 3E−8 
mol/l DEX (Figure 1a) or 3.6E−7 mol/l Cortisol (Figure 1b), with 
highest transfection enhancement for most donors achieved with 
1.2E−7 mol/l DEX or 7.2E−7 mol/l Cortisol, with some donors exhib-
iting a decrease in transfection levels at higher doses (Figure 1). At 
optimal GC dose, all cell donors exhibited an 8–15-fold increase 
in transgene expression (P ≤ 0.001), compared to cells transfected 
under vehicle control conditions. While fold increases remained 
relatively similar across all donors, it should be noted that absolute 
expression levels were different for each donor, ranging across two 
orders of magnitude. Once GCs were determined to be effective 
cell-priming adjuvants, additional metrics of transfection were 
evaluated including transfection efficiency and transgene expres-
sion duration.
To evaluate the ability of GC-priming to enhance transfection 
efficiency, the number of cells expressing the delivered transgene 
out of the total number of treated cells, cells were pretreated as 
before with the optimal dose of DEX (1.2E−7 mol/l) followed by 
delivery of LF-LTX/pEGFP-LUC lipoplexes. Flow cytometry anal-
ysis revealed a 3- to 4-fold increase in the percentage of hMSCs 
expressing green fluorescent protein (GFP) across all cell donors, 
compared to BM and EtOH controls (controls were not statisti-
cally different from each other) (Figure 2a). GC-priming resulted 
in efficiency increases from 2, 5, and 5.5% in unprimed cells to 6.5, 
17.5, and 22% GFP expression following GC-priming in passage 
4 hMSCs for donors D1, D2, and D3, respectively. Representative 
fluorescence microscopy images qualitatively showed this increase 
in transfection efficiency (Figure 2b) in hMSCs primed with DEX 
prior to transfection with pEGFP-LUC compared to unprimed 
cells. As with luciferase expression, while the base level of trans-
fection efficiency across donors was different, the fold increase in 
efficiency as a result of priming was consistent.
In addition to transgene expression levels and transfection effi-
ciency, the duration of these outcomes was evaluated 24, 48, and 
72 hours following DNA delivery in cells primed with 1.2E−7 mol/l 
DEX compared to cells transfected in BM or media with vehicle 
control (EtOH). While overall protein expression decreased with 
time for all treatments, transgene expression was found to remain 
elevated for at least 72 hours in cells primed with DEX compared 
to unprimed cells. Absolute LUC expression levels in unprimed 
cells decreased by 1.5 to 2 orders of magnitude from their highest 
levels at 24 hours, while GC-primed cells showed a decrease in 
LUC expression of only 0.25 to 0.75 orders of magnitude from 
their highest levels at 24 hours for all donors. Additionally, three 
of four hMSC donors expressed luciferase at statistically elevated 
levels following GC-priming compared to the 72 hour con-
trols, and also compared to the highest achievable expression in 
unprimed cells (at 24 hours, P ≤ 0.001) (Figure 3a). Transfection 
efficiency in cells primed with DEX prior to delivery of complexes 
also remained elevated in comparison to unprimed cells for at 
least 72 hours (Figure 3b), with all donors having a 2.5- to 6-fold 
increase in the percentage of GFP-positive cells 72 hours follow-
ing DNA delivery, compared to unprimed cells, which exhibited 
<1.5% GFP at that time
Next the ability of this method to be used across multiple 
nonviral delivery vehicles and with multiple transgenes was inves-
tigated to ensure protocol robustness and applicability to a wide 
range of scientific applications and researchers.
GC-mediated cell priming is effective with multiple 
protocols
For greater applicability of the GC-priming method, additional 
nonviral vehicles and transgenes were evaluated in combination 
with GC-priming. Similar to the effect seen with GC-priming for 
luciferase expression (Figures 1 and Figure 4a), GC-priming sig-
nificantly increased the transfection of the plasmid encoding the 
Table 1 Cell type, donor labels, and demographic data
Cell type Donor ID Gender Age Ethnicity/race
hMSC D1 F 19 Black
hMSC D2 M 20 Caucasian
hMSC D3 F 22 Black
hMSC D4 F 40 Hispanic
hMSC D5 M 22 Black
ASC A1 F 31 Caucasian
ASC, adipose-derived stem cell; hMSC, human mesenchymal stem cell.
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beta-galactosidase (β-gal) gene, with expression increased 4- to 
7-fold over unprimed transfection (Figure 4b). Similarly, GFP pro-
tein levels, as measured by GFP intensity, were also significantly 
increased by 1.75- to 2-fold (Figure 4c) over unprimed transfection.
All experiments reported above were conducted with LF-LTX, 
a transfection reagent specifically formulated for difficult-to-
transfect cells but not as frequently used as Lipofectamine-2000 
(LF-2000) or 25 kDa branched polyethylenimine (PEI), which are 
the two most commonly used vectors for lipid and polymer based 
transfection, respectively. Therefore the ability of GC-priming 
to enhance transfection outcomes following gene delivery with 
multiple commercially available nonviral vectors was evaluated. 
As before, cells were primed 30 minutes prior to DNA delivery 
with 1.2E−7 mol/l DEX followed by delivery of DNA complexes 
prepared with LF-LTX, LF-2000, or PEI containing the pEGFP-
LUC plasmid. Identical transfections were also conducted in BM 
and media containing vehicle control (EtOH) for comparison. 
The BM and EtOH controls were not statistically different from 
each other, while GC-primed treatments resulted in transfection 
levels that were statistically increased relative to transfection lev-
els in unprimed cells for all three nonviral vehicles, with 3.5-to 
5-fold increases in LUC expression for PEI treatments, 5- to 6.75-
fold increases in LUC expression with LF-2000 treatments, and 
8-fold increases in LUC expression following LF-LTX treatments 
(Figure 4d).
Enhanced transfection outcomes and applicability across a 
wide range of nonviral delivery protocols illustrate the poten-
tial of GC-priming for use across multiple platforms to improve 
Figure 1  Glucocorticoid (GC)-priming effect on transgene expression. Human mesenchymal stem cells (hMSCs) exhibit increased luciferase 
expression when primed with dexamethasone (DEX) or cortisol in a dose-dependent manor. Error bars represent standard error of the mean for 
triplicate wells collected on duplicate days. (a) hMSCs primed with DEX exhibit the highest transgene expression in response to 1.2E−7 mol/l DEX 
with an 8- to 13-fold increase in luciferase expression at the optimum dose compared to basal media (BM) alone or with the vehicle control (EtOH). 
(b) Similarly, hMSCs primed with cortisol exhibit an 8- to 15-fold increase in luciferase expression when compared to unprimed cells (BM and EtOH) 
with the optimal cortisol dose of 7.2E−7 mol/l.
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transfection in hMSCs. Next, we investigated potential mecha-
nisms of GC-mediated priming activity and the overall safety of 
GC-priming to maintain normal cellular function.
Mediators of the GC cell-priming effect
GCs are known to bind the GC receptor prior to its transloca-
tion to the cell nucleus.25,26 To determine whether binding of the 
GC receptor was required for the GC-mediated enhancement to 
transfection, a GC receptor antagonist was used to competitively 
bind all GC receptors, prohibiting the delivered DEX from bind-
ing to the GC receptor. As a GC receptor antagonist, Mifepristone 
(RU486) not only binds all receptors preventing GC binding, 
but also prevents the activation of the GC receptor inhibiting 
its nuclear translocation.36 Delivery of RU486 to cells prior to 
GC delivery and subsequent transfection, completely eliminated 
any increase in transgene expression regardless of reporter gene 
(Figure 4a–c), with expression levels in RU486+GC delivery 
equal to transgene expression levels in unprimed cells. These 
results demonstrate that binding of the GC receptor is required 
for enhanced transfection outcomes.
Furthermore, GC-priming may be mediated through 
enhanced cellular and nuclear entry of plasmid DNA due to GCs 
effects on membrane fluidity29 and nuclear pore enlargement.27,28 
To evaluate internalized cellular plasmids and nuclear localized 
plasmids, cells were treated with DEX as described previously. 
Cellular plasmids were quantified via qPCR of DNA isolated from 
whole cell lysates, with total cell numbers calculated by normal-
izing Ct values to the ACTA1 gene, which has exactly two copies 
per cell.37 Nuclear plasmids were quantified similarly, as described 
previously.38 Quantification of total cellular plasmids and plas-
mids from isolated cell nuclei revealed a significant increase in 
both total internalized plasmids and nuclear internalized plas-
mids (Figure 5) in cells primed with DEX, compared to unprimed 
cells transfected in BM or EtOH, with a minimum 5-fold increase 
in total plasmids per cell and a 6.75- to 10.5-fold increase in plas-
mids internalized into the nucleus per cell (P ≤ 0.001). Together, 
these studies suggest that GC-mediated priming enhances trans-
fection through binding of the GR receptor and enhancement of 
cellular and nuclear plasmid internalization.
Cell priming helps maintain normal cellular function
Finally, to corroborate existing literature on the safety of GCs 
on hMSCs, cell viability and hMSC differentiation potential in 
the presence of GC-priming were also evaluated. Nonviral gene 
delivery, while comparably less toxic than viral delivery, can cause 
mild toxicity in vitro or potential inflammatory reactions in vivo. 
Here, hMSCs were treated as described above (GC-primed and 
unprimed) and assayed via WST-1 assay at 24, 48, and 72 hours fol-
lowing treatment to determine metabolic activity for comparison 
to cells without treatment (Figure 6). After 24 hours, no statistical 
Figure 2 Glucocorticoid (GC)-priming effect on transfection efficiency. (a) Cells primed with 1.2E−7 mol/l dexamethasone (DEX) show a minimum 
threefold increase in the number of cells expressing green fluorescent protein (GFP) compared to BM alone or the EtOH controls as evaluated by flow 
cytometry. Error bars represent standard error of the mean for triplicate wells collected on duplicate days. (b) Bright field and fluorescence images of 
human mesenchymal stem cells expressing GFP, either primed with 1.2E−7 mol/l DEX or an equivalent volume of EtOH.
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differences in metabolic activity were found in any of the donors 
between any of the treatments. However, 48 hours after DNA 
delivery, all donors except D2 showed δ no significant decrease in 
metabolic activity between untreated cells and GC-primed treat-
ment, but the unprimed and transfected cells showed a significant 
decrease (P ≤ 0.001) in metabolic activity when compared to the 
untreated cells. Similarly, by 72 hours, all unprimed treatments 
in all donors showed a significant decrease (P ≤ 0.001) in meta-
bolic activity when compared to untreated cells and GC-primed 
transfection, which again were not statistically different. These 
data demonstrate that GC-priming reduces toxicity of nonviral 
vectors in hMSCs by preserving the metabolic activity native to 
untreated cells.
In addition to metabolic activity, stem cells are characterized 
by their ability to differentiate, a potential that must be preserved 
with GC-priming. The adipogenic and osteogenic differentiation 
potential of one cell donor (D2) was evaluated under four condi-
tions: with and without DEX, and with and without transfection. 
Imaging clearly shows the differentiation of hMSCs into osteo-
blasts and adipocytes (Figure 7a,b, respectively) with or with-
out GCs, using standard differentiation media. Quantification 
of osteogenesis by alizarin red absorbance revealed a 0.73-fold 
reduction in osteoblast content in GC-primed transfected cells 
compared to standard differentiation, however a 1.3-fold increase 
in osteoblast differentiation when compared to unprimed trans-
fection in EtOH (Figure 7a). Quantification of adipogenesis by 
oil red O absorbance revealed no statistical difference in adipo-
cyte content between standard differentiation, standard differen-
tiation with DEX and transfection with GC-priming, but showed 
a significant 0.82-fold decrease in adipocyte content in trans-
fected but unprimed cells (Figure 7b). These data demonstrate 
that GC-priming not only maintains the differentiation potential 
of untransfected hMCSs but also preserves their differentiation 
potential following transfection.
In summary, GC-priming enhances transfection efficiency, 
transgene expression and duration, and helps to maintain normal 
Figure 3 Glucocorticoid (GC)-priming effect on duration of enhanced transfection outcomes. (a) The increase in transgene expression due to 
GC-priming remains statistically increased over unprimed cells for at least 72 hours. At 72 hours, all donors express the luciferase transgene at near 
zero relative light unit/mg total protein (RLU/mg), while GC-primed cells not only express transgene at appreciable levels, but donors 1–3 express 
transgene at levels greater than the highest levels without GCs (between 72 hours DEX versus 24 hours BM and EtOH, donors 1 and 2, P ≤ 0.001; D3, 
P ≤ 0.01). Error bars represent standard error (SE) of the mean for triplicate wells collected on duplicate days. (b) In addition to prolonged transgene 
expression levels, the increase in transfection efficiency is also maintained for at least 72 hours when compared to unprimed cells. Error bars represent 
SE of the mean for pooled triplicate wells collected on triplicate days.
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metabolic function and differentiation potential; this effect is 
dependent on GC receptor binding, and mediated in part by 
increased DNA uptake into the cytosol and nucleus.
DISCUSSION
In this study, GCs were evaluated as cell-priming adjuvants to 
enhance transfection outcomes in hMSCs; the delivery of GCs 
was optimized, the effects on transfection were characterized, 
and some of the basic mechanisms underlying the GC-mediated 
effects were elucidated. It was shown that pretreatment of hMSCs 
with GCs (DEX or cortisol) resulted in enhanced transfection 
efficiency 3- to 3.5-fold, increased transgene expression by 4- 
to 15-fold depending on reporter gene, increased cellular DNA 
uptake by 5-fold and nuclear DNA uptake by at least 6-fold, and 
prolonged transgene expression by 24 additional hours all com-
pared to transfection in unprimed cells. These enhancements are 
dependent on GC dose, with the optimal dose varying between 
90–360 nmol/l of DEX from donor to donor. This variation is 
hypothesized to be dependent on physiological GC receptor bind-
ing affinity. Physiological Kd values are between 1–50 nmol/l for 
DEX, depending on donor age, disease status, tissue type, and 
stage of the cell cycle.39–41 Due to the increase in DEX concentra-
tion required to produce enhanced transfection outcomes beyond 
physiological Kd, it is hypothesized that the optimal DEX dose 
(90–360 nmol/l) is the concentration at which receptors become 
saturated with GC rather than 50% bound. Additionally, this dose 
variability is an example of inherent differences in donor response 
similar to the differences in absolute transgene expression levels 
and the rate at which the transient transgene expression declines 
over time as observed across cell donors. These differences indi-
cate a base level of transfection ability and longevity inherent to 
Figure 4 Glucocorticoid (GC)-priming effect with multiple reporter genes and delivery vehicles, and in the presence of a GC receptor antago-
nist. The graphs on the left for (a–c) represent transgene expression magnitude for three different reporter genes (a) Luciferase, (b) B-Galactosidase 
(B-gal), and (c) green fluorescent protein (GFP) intensity as quantified by flow cytometry. Error bars for luciferase expression (a) and B-gal (b) repre-
sent standard error (SE) of the mean for triplicate wells collected on duplicate days, while error bars for GFP expression (c) represent SE of the mean 
for pooled triplicate wells collected on triplicate days. All reporter plasmids show statistically increased expression in GC-primed cells compared to 
the EtOH control. The graphs on the right for (a–c) show the complete knockdown of the GC-priming effect on both (a and b) transgene expression 
and (c) transfection efficiency by the addition of known GC receptor antagonist Mifipristone (RU486), represented as fold change of GC primed cells 
vs. cells treated with both GC and RU486. (d) GC-priming enhances transgene expression using three of the most common commercially available 
nonviral vehicles, 25 kD branched polyethylenimine, Lipofectamine-2000, and Lipofectamine-LTX, with significantly increased expression of 3.5- to 
5-fold, 5- to 6.75-fold, or 8- to 12-fold, respectively, when compared to cells not primed with GCs.
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Figure 5 Glucocorticoid (GC)-priming effect on DNA internalization. 
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cells required to isolate nuclei for qRT-PCR. (a) Total plasmids entering 
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each donor, but also highlight the ability of GC-priming to con-
sistently enhance transfection efficiency and transgene expression 
at similar fold increases over unprimed transfection regardless 
of baseline transfection. As such, we did not make comparisons 
across donors for absolute transgene expression and duration, but 
rather between GC-primed and unprimed cells within each donor 
data set. Unlike the variability in optimal dose, there is variability 
in the fold enhancements of transgene expression with different 
reporter genes. This variability is thought to be a result of gene size 
and protein stability, rather than a function of GC-priming, as evi-
denced by Ribeiro et al.42 who determined smaller genes exhibit 
up to 2.5-fold greater expression over larger genes. LUC and β-gal 
expression were evaluated by similar assays, but likely exhibited 
slightly different fold changes in expression due to their size dif-
ference of 6.37 versus 7.5 kb, respectively.
In addition to enhancing transfection outcomes, GC-priming 
helped transfected hMSCs to maintain the same level of metabolic 
activity as the untransfected hMSCs and helped preserve differen-
tiation potential in both transfected and untransfected controls, 
negating the slight toxicity inherent to nonviral gene delivery. In 
developing novel gene delivery techniques, efficacy and safety are 
always a balancing act, yet with GC-priming, safety is not sacri-
ficed for efficacy, rather both are enhanced. To further corroborate 
these findings, future studies on the preservation of hMSC phe-
notype as evidenced by the presence and absence of traditional 
hMSC surface markers and an investigation into the effects of GC 
priming on apoptosis will be evaluated.
Mechanistically, GR binding was determined to be a cru-
cial factor underlying the ability of GCs to enhance nonviral 
gene delivery. Introduction of a known GC receptor antagonist, 
Mifepristone, completely negated the enhancements to transfec-
tion observed with GC priming (Figure 4), by preventing binding 
of the delivered GC to the receptor. This mechanism pinpoints 
cellular pathways regulated by the GR as key targets for further 
investigation to determine the precise mechanisms, pathways, and 
genes involved in the ability of GCs to prime cells and enhance 
transfection. Another potential mechanism underlying the effects 
of GC-priming on transfection outcomes is enhanced DNA 
uptake into both the cytosol and cell nucleus. CG-primed hMSCs 
showed a 5-fold increase in cytosolic plasmids and at least a 6-fold 
increase in nuclear plasmids compared to unprimed hMSCs. 
However, more work is needed to understand how the GR medi-
ates increased nuclear uptake.
In addition to being difficult-to-transfect, hMSCs also exhibit 
a decline in transfection efficiency with increasing passage num-
ber.18–21 While a decline in absolute transgene expression levels 
was observed with increasing cell passage number, there was no 
variability in the 3- to 4-fold enhancement in transfection across 
cell passage number due to GC-priming (Supplementary Figure 
S2). Due to the known effect of cell passage number on trans-
fection, most other studies have been conducted in passage one 
and two cells, with the highest achieved efficiencies of up to 20% 
observed following lipoplex-mediated gene delivery with de novo 
vehicles.18–20,43 Here, all experiments were conducted in passage 
Figure 6 Glucocorticoid (GC)-priming effect on cellular metabolism. GC-primed cells and untreated cells showed metabolic activity that was not 
statistically different (except for D2 at 48 hours, P ≤ 0.01), while cells treated with EtOH and cells transfected in basal media alone (std. Transfection) 
were also not statistically different. Untreated cells and GC primed cells showed significantly increased metabolic activity when compared to std. 
transfection and EtOH-treated cells at the 48-hour and 72-hour time points (P ≤ 0.001) (except D2 at 48 hours, P ≤ 0.01). All error bars represent 
standard error of the mean for triplicate wells.
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four cells, yet donor 3 (D3, Table 1) hMSCs exhibited an increase 
in transfection efficiency from 5.5% without priming to 22% in 
GC-primed cells. No previous study has achieved such high 
transfection efficiency in hMSCs, even at low passage number 
and particularly not with a commercially available delivery vector. 
Given the known decline in absolute transfection efficiency with 
increasing passage number, it is hypothesized that GC priming 
could enhance the transfection efficiency in low passage hMCSs 
beyond those observed here, a hypothesis that will be evaluated 
in future studies. Still, the ability of GC-priming to enhance trans-
fection efficiencies consistently even across cell passage number 
(passages 3–5), gives researchers and clinicians the ability to pro-
long the therapeutic viability of hMSCs far beyond their previous 
usage of passage one and two only, reducing cost and cell waste.
Typical studies with primary mammalian cells often rely on 
a single donor44,45 or do not carry the same donor across experi-
ments.19,21,46–48 Here, we have provided additional data breadth 
by evaluating transfection outcomes across five human donors, 
further indicating the robustness of GC-priming and uniquely 
providing a rare data set that allows for comparison of transfec-
tion outcomes across multiple donors of varied demograph-
ics (Table  1). While this demographic data requires additional 
donors to draw statistical significance, it provides a good start 
for potentially drawing conclusions about donor specific baseline 
transfection ability based on demographic data, which could be 
used to understand research outcomes, to guide patient-specific 
care, or even to develop cell-based therapeutics or diagnostics 
with the highest efficacy.
Along with hMSCs, other cell types were evaluated for this 
work, with the majority of cell types not showing enhanced transfec-
tion outcomes with GC-priming: HEK 293T, D1/ORL/UVA, NIH 
3T3, and HeLa cell lines did not show enhanced transfection (data 
not shown), although HeLa cells were previously shown to be GC 
responsive following adenoviral DNA delivery.49 However, similar 
to the GC-mediated transfection enhancement in hMSCs, human 
adipose-derived stem cells (ASC) showed enhanced transfection 
outcomes in response to GC-priming (Supplementary Figures S3 
and S4), including a 10.75-fold dose–response increase in transfec-
tion levels, a 7-fold increase in transfection efficiency, and main-
tenance of normal metabolic activity following GC-priming when 
compared to unprimed treatments. While this is preliminary data in 
just a single cell donor, it may provide insight into the types of cells 
that may be responsive to GC priming. In addition to hMSCs and 
ASCs, three previous studies have made note of increased trans-
fection or transduction efficiency in a few immortalized cell lines 
following treatment with DEX using PEI,33 Lipofectin,32 or adeno-
viral32,49 delivery vehicles. This study however, is the first to evalu-
ate three transfection outcomes (efficiency, transgene expression, 
and duration) together, and the first to find efficacy in stem cells 
(hMSCs) across multiple cell donors, delivery vehicles, and trans-
genes. To further enhance the utility of GC-priming to enhance 
nonviral gene delivery, future studies will be conducted with more 
ASC donors, additional cell types and plasmids, and in vivo analysis.
In summary, GC-mediated cell priming is a simple, effective, 
and safe technique for enhancing multiple transfection outcomes to 
levels not previously seen with nonviral delivery in hMSCs. These 
results demonstrate the ability of GC-mediated cell priming to 
enhance multiple transfection outcomes in hMSCs across multiple 
cell donors and passage number with multiple commercially avail-
able transfection reagents and transgenes. The enhancements to 
transfection were found to be dependent on the binding of the GC 
receptor and are mediated in part by maintenance of normal meta-
bolic activity and increased DNA uptake. GC-priming provides 
clinicians and researchers a technique to enhance the transfection 
of hMSCs while maintaining the inherent safety of nonviral gene 
delivery, that can be implemented immediately in combination 
with their current transfection protocols to improve the therapeutic 
potential of these cells in applications such as tissue engineering, the 
treatment of autoimmune diseases, and cancer therapy.
MATERIALS AND METHODS
Cell culture. Bone marrow-derived human mesenchymal stem cells 
(hMSCs) and adipose derived human stem cells (ASCs) (Table 1) were 
purchased at passage 2 from Lonza (Lonza, Walkersville, MD). hMSCs 
Figure 7 Glucocorticoid (GC)-priming effect on human mesenchy-
mal stem cell differentiation potential. All error bars represent the 
 standard deviation of the mean for triplicate wells of differentiated cells. 
(a) Osteogenic differentiation images and spectrophotometric absor-
bance data of Alizarin Red staining, collected at 405 nm and normal-
ized to the negative control. (b) Adipogenic differentiation images and 
spectrophotometric absorbance data of Oil Red O staining, collected at 
540 nm and normalized to the negative control.
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are positive for CD29, CD44, CD105, and CD166 cell surface markers 
and negative for CD14, CD34, and CD45 (Lonza). ASCs are positive for 
CD13, CD29, CD44, CD73, CD90, CD105, CD166, and negative for the 
CD14, CD31, CD45 cell surface markers (Lonza). Cells were expanded 
and cultured in complete MSCGM media (Lonza) for hMSCs or complete 
ADSC media (Lonza) for ASCs and incubated at 37 °C with 5% CO2 until 
80% confluent. Cells were then washed with 1× phosphate-buffered saline 
(PBS) and dissociated with 0.05% trypsin-ethylenediamine tetraacetic acid 
(EDTA) (Gibco, Life Technologies, Grand Island, NY), an equal volume of 
complete media was then added. Cells were counted with trypan blue and 
a hemocytometer, pelleted, and resuspended in 1 ml of media per 6 × 104 
cells and either frozen (in 5% dimethyl sulfoxide) in liquid nitrogen for 
future passages, or seeded for experimentation. Cells were seeded into 48 
or 24 well plates (Thermo Scientific, Rockford, IL) at a density of 6,000 
cells/cm2 for hMSCs or 8,000 cells/cm2 for ASCs, per manufacturer’s proto-
cols. Cells were allowed to adhere for 48 hours at 37 °C with 5% CO2 prior 
to DNA complex delivery.
Priming reagents. DEX, cortisol, and mifepristone (RU486) were pur-
chased from Sigma (Sigma-Aldrich, St. Louis, MO). All reagents were dis-
solved in absolute ethanol (EtOH), stored at −20 °C, then thawed prior 
to delivery in volumes not exceeding 1% total media volume. RU486 was 
delivered 1 hour prior to GCs at a concentration of 1.2 μmol/l. DEX or 
cortisol was delivered to cells 30 minutes prior to DNA delivery at concen-
trations between 1–720 or 1–1,000 nmol/l, respectively. Optimal GC deliv-
ery timing was determined prior to larger scale studies (Supplementary 
Figure S1) As a vehicle control, EtOH was delivered to cells in place of GCs 
at the same time points and volumes as GCs. See Supplementary Figure 
S5 for treatment timeline.
Transfection. Complexes were formed as follows and added drop-wise to 
cell media 48 hours after seeding. All complexes were formed with either 
pEGFP-LUC plasmid DNA (Clonetech, Mountain View, CA), which 
encodes both the enhanced GFP and firefly luciferase protein (LUC), or 
pCMV-LacZ plasmid (Clonetech), which encodes the β-Galactosidase 
(β-gal) protein; both plasmids nonintegrating, produce transient trans-
fection, and are under the direction of a CMV promoter. Plasmids were 
purified from Escherichia coli bacteria using Qiagen (Valencia, CA) regents 
and stored in Tris-EDTA buffer (10 mmol/l Tris, 1 mmol/l EDTA, PH 7.4) 
at −20 °C. Lipoplexes were formed with Lipofectamine LTX (LF-LTX) 
or Lipofectamine 2000 (LF-2000) (both Life Technologies, Grand Island, 
NY), following manufacturer’s instructions. For LF-LTX, complexes were 
formed in serum-free, Opti-MEM media (Life Technologies) by first incu-
bating plasmid DNA and “Plus” reagent diluted in media for 10 minutes at 
room temperature (RT), then adding transfection reagent diluted in media 
to the DNA and “Plus” reagent and incubating an additional 30 minutes 
at RT. For LF-2000, complexes were formed in serum-free, Opti-MEM 
media by adding transfection reagent diluted in media drop-wise to DNA 
in media and incubating for 20 minutes at RT. Lipoplex transfection condi-
tions were optimized by varying lipid to DNA ratio and amount of DNA 
and optimized for high transfection and low cytotoxicity at 1:2 (LF-LTX) 
and 1:1.5 (LF-2000) lipid:DNA ratio and 0.28 μg DNA/cm2 (data not 
shown). For polyplexes, branched 25 kDa PEI (Sigma-Aldrich) was dis-
solved in Tris-buffered saline at 1 mg/ml and stored at −20 °C. Polyplexes 
were formed in 1× Tris-buffered saline solution by dropwise addition of 
PEI solution to DNA solution, briefly vortexed for 10 seconds, and incu-
bated for 15 minutes at RT. Polyplex transfection conditions were opti-
mized by varying nitrogen to phosphate ratio (N:P) and amount of DNA. 
Optimal conditions, for high transfection and low cytotoxicity at N:P of 20 
and 0.32 μg DNA/cm2 of pDNA were used (data not shown).
Fluorescence microscopy. Microscopy was conducted at 24, 48, and 72 
hours following DNA delivery to confirm eGFP protein expression and 
evaluate cell morphology using a Lecia DMI 3000B fluorescence micro-
scope (Lecia Microsystems GmbH, Wetzlar, Germany).
Protein assays. Cells were washed with 1× PBS, then lysed with 200 μl of 
1× reporter lysis buffer (Promega, Madison, WI) and gentle rocking for 
15 minutes at RT. Lysates were stored at −80 °C if not analyzed imme-
diately. Luciferase expression levels were quantified by luminescence in 
relative light units with a Luciferase Assay kit (Promega) and luminometer 
(Turner Designs, Sunnyvale, CA). β-gal activity was quantified by colori-
metric assay using the β-Galactosidase Enzyme Assay System (Promega) 
and spectrophotometer (Beckman Coulter, Indianapolis, IN); absorbances 
collected at 420 nm. Both Luciferase and B-gal transfection levels were 
normalized to total protein levels determined with a Pierce BCA protein 
colorimetric assay (Pierce, Rockford, IL); absorbances collected at 562 nm.
Flow cytometry. Flow cytometry was used to quantify EGFP expression. 
Cells were washed twice with 1× PBS, and dissociated with 0.05% trypsin-
EDTA, an equal volume of growth media was then added. Three wells of 
identical treatments were pooled into 5 ml round bottomed tubes (BD 
Falcon, Bedford, MA) and placed on ice. Flow cytometry was conducted 
on a FACS Calibur (Beckton Dickinson Biosciences, San Jose, CA) with an 
excitation at 488 nm. GFP signal was collected on the FL1 detector using 
a 530/30 band-pass filter. Analysis was performed with a live cell gate in 
forward and side scatter to remove cell debris and clumped cells. A mini-
mum of 5,000 events per treatment was collected for reporting of transfec-
tion efficiency (% GFP). Acquisition and analysis were performed using 
CellQuest Pro (BD Biosciences). Flow cytometry data was collected in 
duplicate (three pooled wells/n) on duplicate days for an n = 4 per donor.
Metabolic activity. Metabolic activity was assessed using a Water Soluble 
Tetrazolium (WST-1) salt cell proliferation assay kit (Roche, Indianapolis, 
IN), according to manufacturer’s protocol. Briefly, cells were washed with 
1× PBS and incubated at 37 °C in WST-1 solution (10 vol% WST-1 reagent 
in phenol-free Dulbecco's Modified Eagle Medium) for 5 hours. After 
incubation, absorbance values were measured on an Epoch Microplate 
spectrophotometer (BioTek, Winooski, VT) at 450 nm.
Plasmid quantification. To quantify plasmids internalized into the cyto-
plasm and cell nucleus, hMSCs were seeded into eight T-75 flasks (Falcon): 
4 DEX treatment, and 4 EtOH control, then transfected as described previ-
ously. After 48 hours, cells were dissociated and four flasks per treatment 
were combined and resuspended in 2 ml of nuclei buffer (10 mmol/l PIPES 
buffer at ph 7.4, 1 mmol/l dithiothreitol, 2 mmol/l MgCl2, 10 mmol/l KCl). 
Cells were incubated at RT in nuclei buffer for 30 minutes, then lysed via 
dounce homogenizer (10 strokes). Treatment lysates were split in half: 1 ml 
for cellular plasmid quantification and 1 ml for nuclear plasmid quantifica-
tion. Nuclei were isolated via iodixanol gradient, as previously described.38 
Nuclei isolation was confirmed by Hoechst stain and fluorescence micros-
copy (data not shown). Both nuclei and whole cell suspension were treated 
with 0.5% sodium dodecyl sulfate and DNA was collected in the aqueous 
phase by phenol extraction and further purified by performing a second 
extraction of the aqueous phase with 25:24:1 phenol/chloroform/isoamyl 
alcohol (Thermo-Fisher). After an ethanol precipitation, the DNA was sus-
pended in ddH2O. DNA quality was assessed by spectrophotometric absor-
bance ratio of 260/280 nm with a NanoDrop (Thermo Scientific) (data not 
shown). Quantification of nuclear plasmids was performed as previously 
described38 using quantitative real-time reverse-transcription polymerase 
chain reaction (qRT-PCR) to determine the number of plasmid copies. 
qRT-PCR data was normalized as previously described37 to cell number 
determined by using the slope obtained for eGFP curve to convert CT value 
obtained for ACTA1 to copy number. ACTA1 was assumed to be a single copy 
gene and to have the same qRT-PCR efficiencies as eGFP; therefore every 
two copies of ACTA1 represent a single cell. ACTA1 primers (IDT, Skokie, 
IL) were designed: Forward 5′-TCAGAAAGATTCCTACGTGGGCGA-3′, 
ACTA1 Reverse 5′-TGTGGTGCCAGATCTTCTCCATGT-3′ and eGFP 
primer sequences were used from.50 Due to the high volume of cells 
required to perform this assay, data points were collected at pooled n = 1 
(from four flasks of treated cells) for each donor and treatment.
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hMSC differentiation. Five differentiation treatments were evaluated for 
adipogenic and osteogenic differentiation: undifferentiated cells, standard 
differentiation, 1.2E−7 M DEX pretreatment followed by standard differentia-
tion, 1.2E−7 M DEX pretreatment and lipofection followed by standard dif-
ferentiation, and EtOH pretreatment and lipofection followed by standard 
differentiation, all following manufacturer’s protocols. Briefly for adipogene-
sis, hMSCs were seeded at 21,000 cells/cm2 for untransfected treatments and 
6,000 cells/cm2 for transfected treatments. Following GC-priming and lipo-
fection as described above, cells were grown to 100% confluence followed 
by three weeks of media changes: three rounds of two days in adipogenic 
induction media then three days in adipogenic maintenance media, end-
ing in seven days in maintenance media. Briefly for osteogenic differentia-
tion, hMSCs were seeded at 3,100 cells/cm2 for untransfected treatments and 
6,000 cells/cm2 for transfected treatments. Following GC-priming and lipo-
fection as described above, cells were immediately differentiated by mainte-
nance in osteogenic cell media for 3 weeks with media changes every 3 days.
Differentiation was evaluated via cell staining and quantified by 
absorbance. After differentiation, cells were washed in 2 ml of 1× PBS 
before fixation in 4% paraformaldehyde (Electron Microscopy Sciences, 
Hatfield, PA) for 20 minutes. Cells were then washed with 2 ml of ddH2O 
per well. For adipose cells, cells were then incubated at RT with 2 ml of 60% 
Isopropanol for five minutes. After incubation, isopropanol was replaced 
with 2 ml of Oil Red O (three parts Oil Red O in two parts 1× PBS) 
(Sigma-Aldrich) and incubated at RT for 5 minutes. After incubation, Oil 
Red O was removed, and cells were washed three times with 2 ml of RT 
ddH2O. Bound Oil Red O was then eluted with 1 ml 99% isopropanol, 
and the elution absorbance was read at 540 nm by spectrophotometer 
(BioTek, Winooski, VT). For osteoblast cells, cells were incubated at RT 
for 45 minutes in 2 ml Alizarin Red (pH 4.2) (Santa Cruz Biotechnology, 
Dallas, TX). Alizarin Red was removed and bound stain was eluted with 
800 μl of 50 °C, 10% acetic acid (v/v) and incubated at RT for 30 minutes. 
Elution absorbance was read at 405 nm by spectrophotometer (BioTek). 
All absorbance data was normalized to the undifferentiated controls.
Statistical analysis. All experiments were performed in triplicate wells 
evaluated on the same day or as pooled triplicate wells evaluated on trip-
licate days (n = 3), unless otherwise noted. Due to the influence of cell 
passage number on stem cell behavior and limited cell availability for 
each donor, no statistical methods were used to predetermine sample 
size. Experiments were conducted with as many donors as possible, based 
on cell availability. All data for independent data points are reported as 
mean ± standard error. Where only one experiment could be conducted, 
data for replicate values are reported as the mean ± standard deviation, 
as noted. Comparative analyses were completed using one- or two-way 
analysis of variance with Bonferroni post-hoc analysis depending on the 
comparisons being drawn. All data collected and analyzed were assumed 
to be normally distributed. Statistical difference was considered at P ≤ 0.01 
(**) and P ≤ 0.001 (***). Statistics and fold changes highlighted within fig-
ures are between primed treatments versus unprimed (EtOH) treatments, 
unless noted. Statistics were calculated using Prism GraphPad software 
(GraphPad Software, La Jolla, CA).
SUPPLEMENTARY MATERIAL
Figure S1. GC delivery time effect on transfection outcomes.
Figure S2. Effect of cell passage number on transfection outcomes 
following GC-priming.
Figure S3. Preliminary data for GC-priming of ASCs.
Figure S4. Fluorescence images of ASCs primed with GCs vs. EtOH 
controls.
Figure S5. Experimental design timeline.
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